Riccardo Perfetti - Jun 3, 2021 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)

Role: Chief Medical Officer
Signature: /s/ Shoshana Shendelman, Attorney-in-Fact
Stock symbol: APLT
Transactions as of: Jun 3, 2021
Transactions value $: -$25,740
Form type: 4
Date filed: 6/7/2021, 09:21 PM
Previous filing: May 26, 2021
Next filing: Jun 30, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLT	Common Stock	Options Exercise	$662	+460		$1.44	460	Jun 3, 2021	Direct	F1
transaction	APLT	Common Stock	Sale	-$9.04K	-460	-100%	$19.66^*	0	Jun 3, 2021	Direct	F2, F3
transaction	APLT	Common Stock	Options Exercise	$662	+460		$1.44	460	Jun 4, 2021	Direct	F1
transaction	APLT	Common Stock	Sale	-$9.04K	-460	-100%	$19.65^*	0	Jun 4, 2021	Direct	F2, F4
transaction	APLT	Common Stock	Options Exercise	$662	+460		$1.44	460	Jun 7, 2021	Direct	F1
transaction	APLT	Common Stock	Sale	-$4.09K	-200	-43.48%	$20.43^*	260	Jun 7, 2021	Direct	F2, F5
transaction	APLT	Common Stock	Sale	-$5.56K	-260	-100%	$21.38^*	0	Jun 7, 2021	Direct	F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLT	Stock Option (Right to Buy)	Options Exercise	$0	-460	-0.27%	$0.00	171K	Jun 3, 2021	Common Stock	460	$1.44	Direct	F1, F7
transaction	APLT	Stock Option (Right to Buy)	Options Exercise	$0	-460	-0.27%	$0.00	170K	Jun 4, 2021	Common Stock	460	$1.44	Direct	F1, F7
transaction	APLT	Stock Option (Right to Buy)	Options Exercise	$0	-460	-0.27%	$0.00	170K	Jun 7, 2012	Common Stock	460	$1.44	Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2	Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3	Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.4900 to $19.7900 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4	Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.5400 to $19.9000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5	Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.9700 to $20.8300 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6	Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.2900 to $21.4500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7	Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.